This study aimed to evaluate the efficacy and safety of olmesartan medoxomil (OM)/amlodipine (AML) 20/5 mg fixed-dose combination tablet in Chinese mild to moderately hypertensive patients with inadequate blood pressure (BP) control on monotherapy. Two multicenter, randomized, double-blind, double-dummy, active-controlled, parallel group clinical trials were conducted. After screening and a 2-week placebo run-in period, patients with 95 mmHg ≤ seated diastolic blood pressure (SeDBP) < 110 mmHg received monotherapy with OM 20 mg (in Study 1) or AML 5 mg (in Study 2), once daily for 4 weeks. Patients with 90 mmHg ≤ mean SeDBP < 110 mmHg at the end of the monotherapy period were randomized to receive OM/AML 20/5 mg treatment or continue with the monotherapy, once daily for 8 weeks. OM/AML (20/5 mg) treatment significantly lowered both systolic and diastolic BP at 4 and 8 weeks compared to 40 mg olmesartan or 5 mg AML. The incidence of drug-related adverse effects did not differ significantly between the groups. OM/AML 20/5 mg was superior to OM 40 mg or AML 5 mg monotherapy in lowering BP in Chinese mild to moderately hypertensive patients with inadequate BP control on monotherapy. No new or unexpected safety issues were identified with OM/AML combination therapy compared to monotherapy.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price includes VAT (USA)
Tax calculation will be finalised during checkout.
Analysis of covariance
Calcium channel blocker
Full analysis set
Least square mean
Per protocol set
Seated diastolic blood pressure
Seated systolic blood pressure
Bakris, G. L., Sarafidis, P. A., Weir, M. R., Dahlof, B., Pitt, B., Jamerson, K., Velazquez, E. J.,Staikos-Byrne, L., Kelly, R. Y., Shi, V., Chiang, Y. T., Weber, M. A. and ACCOMPLISH Trial investigators.(2010). Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 375: 1173–1181.
Bangalore, S., G. Kamalakkannan, S. Parkar, and F.H. Messerli. 2007. Fixed-dose combinations improve medication compliance: A meta-analysis. American Journal of Medicine 120: 713–719.
Chen, X., P. Hu, J. Jiang, T. Liu, W. Zhong, H. Liu, and Q. Zhao. 2012. Pharmacokinetic and pharmacodynamic profiles of a fixed-dose combination of olmesartan medoxomil and amlodipine in healthy Chinese males and females. Clinical Drug Investigation 32: 783–790.
Chrysant, S.G., J. Lee, M. Melino, S. Karki, and R. Heyrman. 2010. Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension. Journal of Human Hypertension 24: 730–738.
Chrysant, S.G., M. Melino, S. Karki, J. Lee, and R. Heyrman. 2008. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clinical Therapeutics 30: 587–604.
Chrysant, S.G., S. Oparil, M. Melino, S. Karki, J. Lee, and R. Heyrman. 2009. Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension. The Journal of Clinical Hypertension 11: 475–482.
Dahlöf, B., P.S. Sever, N.R. Poulter, H. Wedel, D.G. Beevers, M. Caulfield, R. Collins, S.E. Kjeldsen, A. Kristinsson, and G.T. McInnes. 2005. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. The Lancet 366: 895–906.
Darwish, H.W., and A.H. Backeit. 2013. Multivariate versus classical univariate calibration methods for spectrofluorimetric data: Application to simultaneous determination of olmesartan medoxamil and amlodipine besylate in their combined dosage form. Journal of Fluorescence 23: 79–91.
Derosa, G., A.F. Cicero, A. Carbone, F. Querci, E. Fogari, A. D’Angelo, and P. Maffioli. 2014. Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammation. European Journal of Pharmaceutical Sciences 51: 26–33.
Ding, S., J. Liu, Q. Fu, and Y. Zheng. 2013. Clinical effects of combined olmesartan medoxomil and amlodipine on clinic and ambulatory blood pressure in elderly patients with resistant hypertension. Archives of Gerontology and Geriatrics 57(3): 423–427.
Ezzati, M., S. Oza, G. Danaei, and C.J. Murray. 2008. Trends and cardiovascular mortality effects of state-level blood pressure and uncontrolled hypertension in the United States. Circulation 117: 905–914.
Gradman, A.H., J.N. Basile, B.L. Carter, and G.L. Bakris. 2011. Combination therapy in hypertension. Journal of the American Society of Hypertension 13: 146–154.
Hu, S.S., L.Z. Kong, R.L. Gao, M.L. Zhu, W. Wang, Y.J. Wang, Z.S. Wu, W.W. Chen, M.B. Liu, and B. Editorial. 2012. Outline of the report on cardiovascular disease in China, 2010. Biomedical and Environmental Sciences 25: 251–256.
International Conference on Harmonization (ICH) (2014) Topic E9: Statistical Principles for Clinical Trials. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E9/Step4/E9_Guideline.pdf. Retrieved January. 16, 2014.
Lewin, A.J., J.L. Izzo Jr, M. Melino, J. Lee, V. Fernandez, and R. Heyrman. 2013. Combined olmesartan, amlodipine, and hydrochlorothiazide therapy in randomized patients with hypertension: A subgroup analysis of the TRINITY study by age. Drugs and Aging 30: 549–560.
Lewington, S., R. Clarke, N. Qizilbash, R. Peto, R. Collins, and C. Prospective studies. 2002. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360: 1903–1913.
Littlejohn, T. W.,III, Majul, C. R., Olvera, R., Seeber, M., Kobe, M., Guthrie, R., Oigman, W. and Study, I. 2009. Results of treatment with telmisartan–amlodipine in hypertensive patients. The Journal of Clinical Hypertension (Greenwich) 11: 207–213.
Mancia, G., R. Fagard, K. Narkiewicz, J. Redon, A. Zanchetti, M. Bohm, T. Christiaens, R. Cifkova, G. De Backer, A. Dominiczak, M. Galderisi, D.E. Grobbee, T. Jaarsma, P. Kirchhof, S.E. Kjeldsen, S. Laurent, A.J. Manolis, P.M. Nilsson, L.M. Ruilope, R.E. Schmieder, P.A. Sirnes, P. Sleight, M. Viigimaa, B. Waeber, F. Zannad, J. Redon, A. Dominiczak, K. Narkiewicz, P.M. Nilsson, M. Burnier, M. Viigimaa, E. Ambrosioni, M. Caufield, A. Coca, M.H. Olsen, R.E. Schmieder, C. Tsioufis, P. van de Borne, J.L. Zamorano, S. Achenbach, H. Baumgartner, J.J. Bax, H. Bueno, V. Dean, C. Deaton, C. Erol, R. Fagard, R. Ferrari, D. Hasdai, A.W. Hoes, P. Kirchhof, J. Knuuti, P. Kolh, P. Lancellotti, A. Linhart, P. Nihoyannopoulos, M.F. Piepoli, P. Ponikowski, P.A. Sirnes, J.L. Tamargo, M. Tendera, A. Torbicki, W. Wijns, S. Windecker, D.L. Clement, A. Coca, T.C. Gillebert, M. Tendera, E.A. Rosei, E. Ambrosioni, S.D. Anker, J. Bauersachs, J.B. Hitij, M. Caulfield, M. De Buyzere, S. De Geest, G.A. Derumeaux, S. Erdine, C. Farsang, C. Funck-Brentano, V. Gerc, G. Germano, S. Gielen, H. Haller, A.W. Hoes, J. Jordan, T. Kahan, M. Komajda, D. Lovic, H. Mahrholdt, M.H. Olsen, J. Ostergren, G. Parati, J. Perk, J. Polonia, B.A. Popescu, Z. Reiner, L. Ryden, Y. Sirenko, A. Stanton, H. Struijker-Boudier, C. Tsioufis, P. van de Borne, C. Vlachopoulos, M. Volpe, and D.A. Wood. 2013. ESH/ESC guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). European Heart Journal 34: 2159–2219.
Neldam, S., D. Zhu, and H. Schumacher. 2013. Efficacy of telmisartan plus amlodipine in nonresponders to CCB monotherapy. International Journal of Hypertension 2013: 627938.
Nesbitt, S., A. Shojaee, and J.F. Maa. 2013a. Efficacy/safety of a fixed-dose amlodipine/olmesartan medoxomil-based treatment regimen in hypertensive blacks and non-blacks with uncontrolled BP on prior antihypertensive monotherapy. The Journal of Clinical Hypertension (Greenwich) 15: 247–253.
Nesbitt, S.D., A. Shojaee, J.F. Maa, and M.R. Weir. 2013b. Efficacy of an amlodipine/olmesartan treatment algorithm in patients with or without type 2 diabetes and hypertension (a secondary analysis of the BP-CRUSH study). Journal of Human Hypertension 27: 445–452.
Ogihara, T., T. Saruta, H. Rakugi, K. Shimamoto, S. Ito, H. Matsuoka, M. Horiuchi, T. Imaizumi, S. Takishita, and J. Higaki. 2009. Rationale, study design and implementation of the COLM study: The combination of olmesartan and calcium channel blocker or diuretic in high-risk elderly hypertensive patients. Hypertension Research 32: 163–167.
Oparil, S., J. Lee, S. Karki, and M. Melino. 2009. Subgroup analyses of an efficacy and safety study of concomitant administration of amlodipine besylate and olmesartan medoxomil: Evaluation by baseline hypertension stage and prior antihypertensive medication use. Journal of Cardiovascular Pharmacology 54: 427–436.
Philipp, T., T.R. Smith, R. Glazer, M. Wernsing, J. Yen, J. Jin, H. Schneider, and R. Pospiech. 2007. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clinical Therapeutics 29: 563–580.
Punzi, H., J.M. Neutel, D.J. Kereiakes, A. Shojaee, W.F. Waverczak, R. Dubiel, and J.F. Maa. 2010. Efficacy of amlodipine and olmesartan medoxomil in patients with hypertension: The AZOR Trial Evaluating Blood Pressure Reductions and Control (AZTEC) study. Therapeutic Advances in Cardiovascular Disease 4: 209–221.
Punzi, H., A. Shojaee, J.F. Maa, and B.-C. Investigators. 2012. Efficacy and tolerability of fixed-dose amlodipine/olmesartan medoxomil with or without hydrochlorothiazide in Hispanic and non-Hispanic patients whose blood pressure is uncontrolled on antihypertensive monotherapy. Therapeutic Advances in Cardiovascular Disease 6: 149–161.
Punzi, H., A. Shojaee, W.F. Waverczak, and J.F. Maa. 2011. Efficacy of amlodipine and olmesartan medoxomil in hypertensive patients with diabetes and obesity. The Journal of Clinical Hypertension 13: 422–430.
Schmieder, R.E., and M. Bohm. 2011. Efficacy and safety of olmesartan medoxomil plus amlodipine in age, gender and hypertension severity defined subgroups of hypertensive patients. Journal of Human Hypertension 25: 354–363.
Sica, D.A. 2002. Rationale for fixed-dose combinations in the treatment of hypertension: The cycle repeats. Drugs 62: 443–462.
Volpe, M., P. Brommer, U. Haag, and C. Miele. 2009. Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: A randomized, double-blind, parallel-group, multicentre study. Clinical Drug Investigation 29: 11–25.
Wankhede, S.B., S.B. Wadkar, K.C. Raka, and S.S. Chitlange. 2009. Simultaneous estimation of amlodipine besilate and olmesartan medoxomil in pharmaceutical dosage form. Indian Journal of Pharmaceutical Sciences 71: 563–567.
Weber, M.A., S. Julius, S.E. Kjeldsen, H.R. Brunner, S. Ekman, L. Hansson, T. Hua, J.H. Laragh, G.T. McInnes, L. Mitchell, F. Plat, M.A. Schork, B. Smith, and A. Zanchetti. 2004. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet 363: 2049–2051.
Writing Group of the 2010 Chinese Guidelines for the Management of Hypertension. 2011. 2010 Chinese guidelines for the management of hypertension. Chinese Journal of Hypertension 19(701–741): 704.
The authors deeply appreciated the contributions of the study team which included but were not limited to Prof. Ge Junbo, Prof. Sun Ningling, Prof. Wu Zonggui,Prof Ke Yuannan, Prof. Zhao Xiuli, Prof Yang Xinchun, Prof Hua Qi, Prof. Zhao Shuiping, Prof. Yuan Hong, Prof. Ma Hong, Prof. Qi Guoxian, Prof. Li Zhanquan, Prof. Li Xiaodong, Prof. Jiang Yinong, Prof. Chen Yundai, Prof. Zhu Jianhua, Prof. Wang Jian’an, Prof. Lu Guoping.
Conflicts of interest
The authors have no conflicts of interest.
Jun-Ren Zhu, Shu-Yang Zhang and Ping-Jin Gao have contributed equally to this study.
On the behalf of Olmesartan Medoxomil/Amlodipine 20/5 mg Study Group.
Electronic supplementary material
Below is the link to the electronic supplementary material.
About this article
Cite this article
Zhu, JR., Zhang, SY. & Gao, PJ. Efficacy and safety of olmesartan medoxomil/amlodipine fixed-dose combination for hypertensive patients uncontrolled with monotherapy. Arch. Pharm. Res. 37, 1588–1598 (2014). https://doi.org/10.1007/s12272-014-0446-x
- Olmesartan medoxomil
- Fixed-dose combination